Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 10/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416040 | 0.90 | DRD2 (0.61) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL1515163 | 0.85 | HTR2C (0.75) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL16615614 | 0.84 | DRD2 (0.51) | DRD2MEN1KMT2AHTR2C | |
| SCHEMBL19773023 | 0.82 | DRD2 (1.00) | DRD2MEN1KMT2AATMGRM2 | |
| SCHEMBL24877624 | 0.81 | HTR2C (0.56) | DRD2MEN1KMT2AHTR2C | |
| SCHEMBL8304330 | 0.81 | DRD2 (0.78) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL13801264 | 0.81 | DRD2 (0.60) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL15832871 | 0.81 | DRD2 (0.60) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL4747037 | 0.81 | DRD2 (0.76) | DRD2MEN1KMT2AHTR2CATM | |
| SCHEMBL9001267 | 0.81 | DRD2 (0.76) | DRD2MEN1KMT2AHTR2CATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
| EP-0819126-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT 1D? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031508-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | DRD2 4710/4885MEN1 569/4885KMT2A 2684/4885 |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | DRD2 3295/4885MEN1 4371/4885KMT2A 2535/4885 |
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | FBL, HNRNPA1, HNRNPUL1 | DRD2 4230/4885MEN1 2364/4885KMT2A 1075/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885MEN1 4777/4885KMT2A 988/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | DRD2 202/4885MEN1 4777/4885KMT2A 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.